Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal furosemide in peritoneal dialysis patients
2024-519356-87-00Phase 4Authorised
- Sponsor
- Foundation for the Incentive of Research
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of furosemide in end-stage kidney disease (ESKD) and heart failure (HF), sponsored by Foundation for the Incentive of Research. Primary endpoints: efficacy and safety measures, reduction in body fluid volume and 7 more. Planned start Mar 2025; status: authorised.
02
Drugs
furosemide
03
Conditions
end-stage kidney disease (ESKD)heart failure (HF)
Beyond the preview
Go deeper on 2024-519356-87-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519356-87-00.